Month: October 2021

Sorry, Readability was unable to parse this page for content.

MILAN (Reuters) - Seven months after the second dose, there is no reduction in the efficacy of COVID-19 mRNA vaccines in the general population in Italy, while a slight decline is seen for some specific groups, the National Health Institute (ISS) said on Wednesday. The report led by ISS and the health ministry examined data up to Aug. 29 from more than 29 million people who had received two doses of an mRNA vaccine such as those produced by Pfizer and Moderna. It said that in the general population, effectiveness against infection after seven months remained at 89%, while against hospitalisation and death, this time six months after the second dose, it remained at 96% and 99% respectively. The findings on protection from infection differ from a study carried out by Pfizer and published o...

...

State health officials on Wednesday reported 836 new cases of COVID-19 on Wednesday and 29 additional deaths. The Maine Center for Disease Control and Prevention initially reported only 300 cases and nine deaths early Wednesday but then revised those numbers, saying an IT system upgrade did not include all the data processed on Tuesday. The CDC alerted media to the problem late Wednesday morning and released the new data hours later. The state’s seven-day daily case average increased to 593, up from from 457 two weeks ago and from 316 cases on average this time last month. Since the pandemic began, there have been 93,201 confirmed or probable cases and 1,065 deaths. One of the deaths reported Wednesday was a person in their 30s, just the fourth such death in Maine. Despite the h...

Sorry, Readability was unable to parse this page for content.

Called Mosquirix, the new vaccine is given in three doses between ages 5 and 17 months, and a fourth dose roughly 18 months later. Following the clinical trials, the vaccine was tried out in three countries — Kenya, Malawi and Ghana — where it was incorporated into routine immunization programs. More than 2.3 million doses have been administered in those countries, reaching more than 800,000 children. That bumped up the percentage of children protected against malaria in some way to more than 90 percent from less than 70 percent, Dr. Hamel said. “The ability to reduce inequities in access to malaria prevention — that’s important,” Dr. Hamel said. “It was impressive to see that this could reach children who are currently not being protected.” It took years to create an efficient system to ...